(INCY) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 20, 2013
(Benzinga,
11/18/11)
Today, Incyte (NASDAQ: INCY) announced that the FDA had approved their blood cancer drug Jakafi that's designed to treat myelofibrosis. The drug is the first to be approved to treat...(read more)
(Stock Blog Hub,
6/16/11)
We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00.
Incyte is a Wilmington, Delaware-based drug discovery and...(read more)
(Wall Street Sector Selector,
5/4/11)
Yesterday we showed you the Boxer Shorts and what they were doing. Certainly there are a lot of negative looking charts, but there are still a lot of bullish ones. Despite the fact that the market had some difficult sessions the last few days, w...
Incyte (INCY) Company Overview
There is no analysis for INCY yet. But you can go to Wikinvest to help create one!
